91 related articles for article (PubMed ID: 31216262)
1. Corrigendum to: SIAH1/ZEB1/IL-6 axis is involved in doxorubicin (Dox) resistance of osteosarcoma cells.
Han X; Liu F; Zhang C; Ren Z; Li L; Wang G
Biol Chem; 2019 Aug; 400(9):1241. PubMed ID: 31216262
[No Abstract] [Full Text] [Related]
2. SIAH1/ZEB1/IL-6 axis is involved in doxorubicin (Dox) resistance of osteosarcoma cells.
Han X; Liu F; Zhang C; Ren Z; Li L; Wang G
Biol Chem; 2019 Mar; 400(4):545-553. PubMed ID: 30265649
[TBL] [Abstract][Full Text] [Related]
3. ZEB1 mediates doxorubicin (Dox) resistance and mesenchymal characteristics of hepatocarcinoma cells.
Long L; Xiang H; Liu J; Zhang Z; Sun L
Exp Mol Pathol; 2019 Feb; 106():116-122. PubMed ID: 30615851
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase 6 regulated expression of IL-8 is involved in the doxorubicin (Dox) resistance of osteosarcoma cells via modulating ABCB1 transcription.
Cheng M; Cai W; Huang W; Chen Y; Wu Z; Luo P; Yan W
Eur J Pharmacol; 2018 Dec; 840():1-8. PubMed ID: 30273544
[TBL] [Abstract][Full Text] [Related]
5. Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression.
Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Biomed Pharmacother; 2019 Oct; 118():109356. PubMed ID: 31545293
[TBL] [Abstract][Full Text] [Related]
6. Improving the cytometric detection of doxorubicin resistance in osteosarcoma cells by determining cellular doxorubicin/DNA ratio.
Takeshita H; Kusuzaki K; Murata H; Nakamura S; Ashihara T; Hirasawa Y
Anticancer Res; 1999; 19(6B):5235-8. PubMed ID: 10697541
[TBL] [Abstract][Full Text] [Related]
7. Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.
Buondonno I; Gazzano E; Jean SR; Audrito V; Kopecka J; Fanelli M; Salaroglio IC; Costamagna C; Roato I; Mungo E; Hattinger CM; Deaglio S; Kelley SO; Serra M; Riganti C
Mol Cancer Ther; 2016 Nov; 15(11):2640-2652. PubMed ID: 27466354
[TBL] [Abstract][Full Text] [Related]
8. Alopecurone B reverses doxorubicin-resistant human osteosarcoma cell line by inhibiting P-glycoprotein and NF-kappa B signaling.
Xia YZ; Ni K; Guo C; Zhang C; Geng YD; Wang ZD; Yang L; Kong LY
Phytomedicine; 2015 Mar; 22(3):344-51. PubMed ID: 25837271
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin and edelfosine lipid nanoparticles are effective acting synergistically against drug-resistant osteosarcoma cancer cells.
González-Fernández Y; Imbuluzqueta E; Zalacain M; Mollinedo F; Patiño-García A; Blanco-Prieto MJ
Cancer Lett; 2017 Mar; 388():262-268. PubMed ID: 27998763
[TBL] [Abstract][Full Text] [Related]
10. Stathmin is key in reversion of doxorubicin resistance by arsenic trioxide in osteosarcoma cells.
Feng T; Qiao G; Feng L; Qi W; Huang Y; Yao Y; Shen Z
Mol Med Rep; 2014 Dec; 10(6):2985-92. PubMed ID: 25310700
[TBL] [Abstract][Full Text] [Related]
11. Folic acid decorated metal-organic frameworks loaded with doxorubicin for tumor-targeted chemotherapy of osteosarcoma.
Xu W; Lou Y; Chen W; Kang Y
Biomed Tech (Berl); 2020 Apr; 65(2):229-236. PubMed ID: 31605575
[TBL] [Abstract][Full Text] [Related]
12. Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway.
Wang Z; Yang L; Xia Y; Guo C; Kong L
Biol Pharm Bull; 2015; 38(2):277-84. PubMed ID: 25747987
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
Gazzano E; Buondonno I; Marengo A; Rolando B; Chegaev K; Kopecka J; Saponara S; Sorge M; Hattinger CM; Gasco A; Fruttero R; Brancaccio M; Serra M; Stella B; Fattal E; Arpicco S; Riganti C
Cancer Lett; 2019 Aug; 456():29-39. PubMed ID: 31047947
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA LINC00426 contributes to doxorubicin resistance by sponging miR-4319 in osteosarcoma.
Wang L; Luo Y; Zheng Y; Zheng L; Lin W; Chen Z; Wu S; Chen J; Xie Y
Biol Direct; 2020 Jul; 15(1):11. PubMed ID: 32620145
[TBL] [Abstract][Full Text] [Related]
15. Oxidative stress induced by low-dose doxorubicin promotes the invasiveness of osteosarcoma cell line U2OS in vitro.
Shin SH; Choi YJ; Lee H; Kim HS; Seo SW
Tumour Biol; 2016 Feb; 37(2):1591-8. PubMed ID: 26298721
[TBL] [Abstract][Full Text] [Related]
16. Avoidance of doxorubicin resistance in osteosarcoma cells using a new quinoline derivative, MS-209.
Takeshita H; Kusuzaki K; Tsuji Y; Hirata M; Hashiguchi S; Nakamura S; Murata H; Ashihara T; Hirasawa Y
Anticancer Res; 1998; 18(2A):739-42. PubMed ID: 9615713
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy.
Wang Z; Liu Z; Wu S
Oncotarget; 2017 May; 8(19):31465-31477. PubMed ID: 28415557
[TBL] [Abstract][Full Text] [Related]
18. Reversal of multidrug resistance by icaritin in doxorubicin-resistant human osteosarcoma cells.
Wang ZD; Wang RZ; Xia YZ; Kong LY; Yang L
Chin J Nat Med; 2018 Jan; 16(1):20-28. PubMed ID: 29425587
[TBL] [Abstract][Full Text] [Related]
19. Autophagy prevents doxorubicin‑induced apoptosis in osteosarcoma.
Zhao D; Yuan H; Yi F; Meng C; Zhu Q
Mol Med Rep; 2014 May; 9(5):1975-81. PubMed ID: 24639013
[TBL] [Abstract][Full Text] [Related]
20. The survivin suppressant YM155 reverses doxorubicin resistance in osteosarcoma.
Zhang Z; Zhang Y; Lv J; Wang J
Int J Clin Exp Med; 2015; 8(10):18032-40. PubMed ID: 26770398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
